DE69633231D1 - Tnf-alpha konvertierendes enzym - Google Patents

Tnf-alpha konvertierendes enzym

Info

Publication number: DE69633231D1
Authority: DE; Germany
Prior art keywords: tnf; protease; converting enzyme; alpha converting; isolated
Prior art date: 1995-06-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE69633231T

Other languages

English (en)

Other versions

DE69633231T2 (de

Inventor

Roy A Black

Charles Rauch

Carl J March

Douglas P Cerretti

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Immunex Corp

Original Assignee

Immunex Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-08

Filing date

1996-06-03

Publication date

2004-09-30

1996-05-23 Priority claimed from US08/655,345 external-priority patent/US5830742A/en

1996-06-03 Application filed by Immunex Corp filed Critical Immunex Corp

2004-09-30 Publication of DE69633231D1 publication Critical patent/DE69633231D1/de

2005-08-04 Application granted granted Critical

2005-08-04 Publication of DE69633231T2 publication Critical patent/DE69633231T2/de

2016-06-04 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

102000043279 ADAM17 Human genes 0.000 title 1
108091007505 ADAM17 Proteins 0.000 title 1
108091005804 Peptidases Proteins 0.000 abstract 3
239000004365 Protease Substances 0.000 abstract 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 3
GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 abstract 1
102000005741 Metalloproteases Human genes 0.000 abstract 1
108010006035 Metalloproteases Proteins 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
239000002299 complementary DNA Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Urology & Nephrology (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Biotechnology (AREA)
Heart & Thoracic Surgery (AREA)
Microbiology (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)

DE69633231T 1995-06-08 1996-06-03 Tnf-alpha konvertierendes enzym Expired - Fee Related DE69633231T2 (de)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US48245895A	1995-06-08	1995-06-08
US33169P		1995-06-08
US50461495A	1995-07-20	1995-07-20
US504614		1995-07-20
US655345		1996-05-23
US08/655,345 US5830742A (en)	1995-06-08	1996-05-23	TNF-α converting enzyme
PCT/US1996/008407 WO1996041624A1 (en)	1995-06-08	1996-06-03	TNF-α CONVERTING ENZYME

Publications (2)

Publication Number	Publication Date
DE69633231D1 true DE69633231D1 (de)	2004-09-30
DE69633231T2 DE69633231T2 (de)	2005-08-04

Family

ID=27413615

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69633231T Expired - Fee Related DE69633231T2 (de)	1995-06-08	1996-06-03	Tnf-alpha konvertierendes enzym

Country Status (13)

Country	Link
EP (1)	EP0830130B9 (de)
JP (1)	JP4326022B2 (de)
AT (1)	ATE274346T1 (de)
AU (1)	AU712759C (de)
CA (1)	CA2222650C (de)
DE (1)	DE69633231T2 (de)
DK (1)	DK0830130T3 (de)
ES (1)	ES2227598T3 (de)
IL (1)	IL122305A0 (de)
NO (1)	NO323623B1 (de)
NZ (2)	NZ312285A (de)
PT (1)	PT830130E (de)
WO (1)	WO1996041624A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6180403B1 (en)	1999-10-28	2001-01-30	Isis Pharmaceuticals Inc.	Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
US6255064B1 (en)	1996-03-01	2001-07-03	The Procter & Gamble Company	Disintegrin metalloprotease and its use
AU2291397A (en) *	1996-03-26	1997-10-17	Glaxo Group Limited	Tumor necrosis factor alpha convertase
JP2000500660A (ja) *	1996-07-12	2000-01-25	シェーリングコーポレイション	哺乳動物ＴＮＦ―αコンベルターゼ
US5853977A (en) *	1996-07-12	1998-12-29	Schering Corporation	Mammalian TNF-α convertases
EP0988385A2 (de) *	1997-01-21	2000-03-29	Human Genome Sciences	Polypeptide, die tace und matrilysin ähneln.
AU6181798A (en) *	1997-02-25	1998-09-09	Case Western Reserve University	Use of a novel disintegrin metalloprotease, mutants, fragments and the ike
US6551857B2 (en)	1997-04-04	2003-04-22	Elm Technology Corporation	Three dimensional structure integrated circuits
US6548633B1 (en)	1998-12-22	2003-04-15	Genset, S.A.	Complementary DNA's encoding proteins with signal peptides
CN1342200A (zh) *	1998-02-04	2002-03-27	免疫检查公司	晶体TNF－α－转换酶及其应用
US6842704B2 (en)	1998-02-04	2005-01-11	Immunex Corporation	Crystalline TNF-α-converting enzyme and uses thereof
US6632667B1 (en)	1999-10-28	2003-10-14	Isis Pharmaceuticals, Inc.	Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
EP1449538A1 (de) *	2003-02-21	2004-08-25	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Modulation der EGF Rezeptor Signalübertragung durch Hemmung von TACE oder Amphiregulin
WO2005030798A2 (en)	2003-09-24	2005-04-07	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	TNFαCONVERTING ENZYME INHIBITORY AGENTS AND STIMULATORY AGENTS-
BRPI0716139A2 (pt) *	2006-08-28	2013-09-17	Ares Trading Sa	processo para purificaÇço de proteÍnas de fusço fc
US8513393B2 (en) *	2006-08-28	2013-08-20	Ares Trading S.A.	Process for the purification of Fc-containing proteins
JP2014511372A (ja)	2011-02-01	2014-05-15	キャンサー・リサーチ・テクノロジー・リミテッド	抗ｔａｃｅ抗体分子及びその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE148992T1 (de) *	1989-08-16	1997-03-15	Chiron Corp	Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
AU641178B2 (en) *	1989-08-16	1993-09-16	Cetus Oncology Corp	Prohormone cleavage site blocking antibody
EP0535059B1 (de) *	1990-06-22	1995-11-29	Jens LÜDEMANN	Dna-sequenz für eine serin-protease und damit zusammenhängende gegenstände
WO1992002822A1 (en) *	1990-08-06	1992-02-20	Cetus Corporation	Methods for the identification of cytokine convertase inhibitors
EP0648225A1 (de) *	1992-06-25	1995-04-19	Chiron Corporation	Zusammensetzungen zur inhibition der bildung von proteinhormonen und anwendungen davon
WO1995024501A1 (en) *	1994-03-07	1995-09-14	Cetus Oncology Corporation	Compositions for the inhibition of tnf formation and uses thereof
AU2291397A (en) *	1996-03-26	1997-10-17	Glaxo Group Limited	Tumor necrosis factor alpha convertase

1996
- 1996-06-03 DK DK96923209T patent/DK0830130T3/da active
- 1996-06-03 ES ES96923209T patent/ES2227598T3/es not_active Expired - Lifetime
- 1996-06-03 WO PCT/US1996/008407 patent/WO1996041624A1/en active IP Right Grant
- 1996-06-03 AT AT96923209T patent/ATE274346T1/de not_active IP Right Cessation
- 1996-06-03 IL IL12230596A patent/IL122305A0/xx not_active IP Right Cessation
- 1996-06-03 JP JP50310797A patent/JP4326022B2/ja not_active Expired - Fee Related
- 1996-06-03 EP EP96923209A patent/EP0830130B9/de not_active Expired - Lifetime
- 1996-06-03 PT PT96923209T patent/PT830130E/pt unknown
- 1996-06-03 AU AU63781/96A patent/AU712759C/en not_active Ceased
- 1996-06-03 CA CA002222650A patent/CA2222650C/en not_active Expired - Fee Related
- 1996-06-03 DE DE69633231T patent/DE69633231T2/de not_active Expired - Fee Related
- 1996-06-03 NZ NZ312285A patent/NZ312285A/en not_active IP Right Cessation
- 1996-06-03 NZ NZ510390A patent/NZ510390A/xx not_active IP Right Cessation
1997
- 1997-11-26 NO NO19975438A patent/NO323623B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0830130B1 (de)	2004-08-25
NO323623B1 (no)	2007-06-18
AU712759B2 (en)	1999-11-18
NZ312285A (en)	2001-04-27
CA2222650A1 (en)	1996-12-27
NO975438L (no)	1998-02-06
EP0830130A4 (de)	2000-03-29
AU6378196A (en)	1997-01-09
PT830130E (pt)	2004-11-30
JP4326022B2 (ja)	2009-09-02
IL122305A0 (en)	1998-04-05
DE69633231T2 (de)	2005-08-04
MX9709744A (es)	1998-07-31
ES2227598T3 (es)	2005-04-01
EP0830130B9 (de)	2004-12-29
JP2002515020A (ja)	2002-05-21
NO975438D0 (no)	1997-11-26
EP0830130A1 (de)	1998-03-25
CA2222650C (en)	2009-10-13
NZ510390A (en)	2002-11-26
ATE274346T1 (de)	2004-09-15
DK0830130T3 (da)	2004-12-20
WO1996041624A1 (en)	1996-12-27
AU712759C (en)	2001-08-09

Publication	Publication Date	Title
DE69633231D1 (de)	2004-09-30	Tnf-alpha konvertierendes enzym
UY27972A1 (es)	2004-04-30	Derivados de hidantoína
BG101841A (bg)	1998-04-30	Инхибитори на клетъчна адхезия
TR199802694T2 (xx)	1999-03-22	IL-8 resept�r kar��tlar�
DK0966465T3 (da)	2003-10-20	Inhibitorer af IMPDH-enzymer
BG103977A (en)	2000-11-30	Low molecular rotamase enzymic activity inhibitors
NO20004053L (no)	2000-09-11	Glukokortikoid-selektive antiinflammatoriske midler
DE69825904D1 (de)	2004-09-30	Mutante alpha-amylase mit zusätzlicher disulfidverbindung
EA200100103A1 (ru)	2001-06-25	Ингибиторы адгезии клеток
BR9507237A (pt)	1997-09-16	Protease altamente alcalina e sua aplicação
ATE199090T1 (de)	2001-02-15	Gegenüber eigenen inhibitoren resistente t-pa mutanten
DK1053240T3 (da)	2003-08-11	Glucocorticoid-selektiv antiinflammatoriske midler
MA26492A1 (fr)	2004-12-20	Inhibiteurs de proteases nouveaux et compositions pharmaceutiques les contenant .
DE3671021D1 (de)	1990-06-13	Peptid-derivate, pepstatin-analoga, renin- und saeureprotease hemmende mittel.
DE69625506D1 (de)	2003-01-30	Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung
DK0869970T3 (da)	2004-07-05	Endothelcelleprolifereringsinhibitor og dens anvendelse
ES2171563T3 (es)	2002-09-16	Nueva familia de inhibidores de proteasas, y otras sustancias de actividad biologica.
MA26540A1 (fr)	2004-12-20	Composes nouveaux inhibiteurs de proteases et compositions pharmaceutiques les contenant.
ATE238062T1 (de)	2003-05-15	Hemmung von hiv-infektion
WO1999001567A3 (en)	1999-04-01	Methods and compositions for a deubiquitinating enzyme and variants thereof
BR9608978A (pt)	1999-06-29	Inibidor de protease de serina derivado de imidazo [1,5a] piridina composição farmacêutica e utilização do inibidor de protease
DE69710752D1 (de)	2002-04-04	Kombinationstherapie für die behandlung von arthritis erkrankungen
DE60220185D1 (de)	2007-06-28	Screening-verfahren für substanzen zur behandlung von diabetes
DE3774947D1 (de)	1992-01-16	Alpha-acylamino-aminoalkyl-phosphonat-inhibitor des angiotensin umwandelnden enzyms.
FR2837836B1 (fr)	2005-04-22	UTILISATION DE LA PROTEINE Maba (FABG1) DE MYCOBACTERIUM TUBERCULOSIS POUR LA CONCEPTION ET LE CRIBLAGE D'ANTIBIOTIQUES

Legal Events

Date	Code	Title	Description
2005-09-22	8364	No opposition during term of opposition
2008-07-03	8328	Change in the person/name/address of the agent	Representative=s name: BOCKHORNI & KOLLEGEN, 80687 MUENCHEN
2011-04-21	8339	Ceased/non-payment of the annual fee